Scilex Holding (SCLX) Change in Accured Expenses (2021 - 2026)

Scilex Holding (SCLX) recorded quarterly Change in Accured Expenses of -$7.8 million in Q1 2026, down 2563.82% quarter-over-quarter from -$293000.0 in Q4 2025, and down 1028.06% on a YoY basis from $841000.0 in Q1 2025.

Scilex Holding (SCLX) Change in Accured Expenses (2021 - 2026) Analysis & Trends

Scilex Holding's Change in Accured Expenses history runs 6 years deep, the most recent figure standing at -$7.8 million for Q1 2026.

  • In Q1 2026, Change in Accured Expenses fell 1028.06% year-over-year to -$7.8 million; the TTM figure through Mar 2026 stood at $6.0 million (up 170.51% YoY), while the FY2025 annual figure was $14.6 million, up 278.78% from the prior year.
  • Change in Accured Expenses was -$7.8 million for Q1 2026 at Scilex Holding, down from -$293000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $14.3 million in Q3 2025 to a low of -$10.6 million in Q4 2024.
  • Historically, Change in Accured Expenses has averaged $32176.5 across 5 years, with a median of -$126000.0 in 2022.
  • The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses tumbled 19597.95% in 2022, then soared 29625.0% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at $981000.0 in 2022, then slumped by 427.73% to -$3.2 million in 2023, then slumped by 230.64% to -$10.6 million in 2024, then surged by 97.24% to -$293000.0 in 2025, then plunged by 2563.82% to -$7.8 million in 2026.
  • The last three Change in Accured Expenses figures came in at -$7.8 million (Q1 2026), -$293000.0 (Q4 2025), and $14.3 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Gsk 93,026,132.38 Bn 93,026,127.42 Bn 7.76 Bn -
2 Eli Lilly 1,022.62 Bn 1,017.34 Bn 16.22 Bn -
3 Johnson & Johnson 570.65 Bn 548.59 Bn 15.96 Bn -629.00 Mn
4 AbbVie 398.73 Bn 389.38 Bn 10.78 Bn -1.59 Bn
5 Merck 295.53 Bn 289.88 Bn 12.09 Bn -
6 Amgen 186.30 Bn 174.26 Bn 5.87 Bn -75.00 Mn
7 Gilead Sciences 155.93 Bn 148.21 Bn 5.52 Bn -702.00 Mn
8 Pfizer 146.09 Bn 133.32 Bn -1.21 Bn -
9 Bristol Myers Squibb 114.98 Bn 104.53 Bn 8.07 Bn -3.50 Bn
10 Scilex Holding 48.31 Mn -101.62 Mn 4.15 Mn -7.81 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -7.81 Mn
Mar 31, 2026 -7.81 Mn
Dec 31, 2025 -293,000.00
Dec 31, 2025 -293,000.00
Sep 30, 2025 14.30 Mn
Sep 30, 2025 14.30 Mn
Jun 30, 2025 -242,000.00
Jun 30, 2025 -242,000.00
Mar 31, 2025 841,000.00
Mar 31, 2025 841,000.00
Dec 31, 2024 -10.63 Mn
Dec 31, 2024 -10.63 Mn
Sep 30, 2024 1.99 Mn
Sep 30, 2024 1.99 Mn
Jun 30, 2024 -650,000.00
Jun 30, 2024 -650,000.00
Mar 31, 2024 1.12 Mn
Mar 31, 2024 1.12 Mn
Dec 31, 2023 -3.22 Mn
Dec 31, 2023 -3.22 Mn